Impact of maximal response on the outcome in newly diagnosed patients treated with high-dose therapy
| Author . | No. of patients . | Comparison . | EFS/PFS . | OS . |
|---|---|---|---|---|
| Single ASCT | ||||
| Björkstrand et al24 | 130 | R | NA | OS benefit (CR vs non-CR) |
| Attal et al18 | 200 | P | NA | OS benefit (≥ VGPR vs PR) |
| Lahuerta et al25 | 344 | R | EFS benefit (CR vs n-CR, VGPR and PR; no difference between n-CR, VGPR and PR | OS benefit (CR vs n-CR VGPR, PR; no difference between n-CR, VGPR, PR) |
| Child et al26 | 407 | P | NA | OS benefit (CR vs PR) |
| Alvares et al27 | 387 | R | PFS benefit (CR vs non-CR) | OS benefit (CR vs non-CR) |
| O'Shea et al28 | 211 | R | EFS benefit (CR vs PR) | OS benefit (CR vs PR) |
| Lenhoff et al29 | 247 | P | EFS benefit (CR vs non-CR) | No OS benefit (CR vs non-CR) |
| Double ASCT | ||||
| Barlogie et al21 | 231 | P | EFS benefit (CR vs PR) | No OS benefit (CR vs PR) |
| Attal et al30 | 399 | P | NA | OS benefit (≥ VGPR) |
| Cavo et al31 | 321 | P | EFS benefit (CR plus n-CR) | OS benefit (CR plus n-CR) |
| Sonneveld et al32 | 303 | P | EFS and PFS benefit (CR) | No OS benefit of CR |
| Harousseau et al20 | 802 | P | EFS benefit (≥ VGPR vs PR) | OS benefit (≥ VGPR vs PR) |
| Author . | No. of patients . | Comparison . | EFS/PFS . | OS . |
|---|---|---|---|---|
| Single ASCT | ||||
| Björkstrand et al24 | 130 | R | NA | OS benefit (CR vs non-CR) |
| Attal et al18 | 200 | P | NA | OS benefit (≥ VGPR vs PR) |
| Lahuerta et al25 | 344 | R | EFS benefit (CR vs n-CR, VGPR and PR; no difference between n-CR, VGPR and PR | OS benefit (CR vs n-CR VGPR, PR; no difference between n-CR, VGPR, PR) |
| Child et al26 | 407 | P | NA | OS benefit (CR vs PR) |
| Alvares et al27 | 387 | R | PFS benefit (CR vs non-CR) | OS benefit (CR vs non-CR) |
| O'Shea et al28 | 211 | R | EFS benefit (CR vs PR) | OS benefit (CR vs PR) |
| Lenhoff et al29 | 247 | P | EFS benefit (CR vs non-CR) | No OS benefit (CR vs non-CR) |
| Double ASCT | ||||
| Barlogie et al21 | 231 | P | EFS benefit (CR vs PR) | No OS benefit (CR vs PR) |
| Attal et al30 | 399 | P | NA | OS benefit (≥ VGPR) |
| Cavo et al31 | 321 | P | EFS benefit (CR plus n-CR) | OS benefit (CR plus n-CR) |
| Sonneveld et al32 | 303 | P | EFS and PFS benefit (CR) | No OS benefit of CR |
| Harousseau et al20 | 802 | P | EFS benefit (≥ VGPR vs PR) | OS benefit (≥ VGPR vs PR) |
Summary of largest studies (> 100 patients).
EFS indicates event-free survival; PFS, progression-free survival; OS, overall survival; ASCT, autologous stem cell transplantation; R, retrospective; CR, complete response; P, prospective; VGPR, very good partial response; PR, partial response; n-CR, near complete response; and NA, not available.